drugset / Trial / NCT02917629
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
RandomizedParallel-groupDouble-blindPrevention
Summary
This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from forming or coming back. The use of ACTOplus met XR may slow disease progression in patients with oral cavity or oropharynx cancer.
Timeline
- Start
- 2018-05-31
- Primary completion
- 2019-08-28
- Completion
- 2019-08-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformide | Unknown | — | Oral |
| Subject | Pioglitazone | Small molecule | — | Oral |